We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Identifies Potential Marker of Targeted Therapy Resistance in Breast Cancer

A new fluorescent sensor tracks cell-cycle activity to flag targeted therapy resistance in ER-positive breast cancer. More...
03 Nov 2026
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

An AI framework aligns CNNs, Vision Transformers, and GNNs with pathology diagnosis, segmentation, and prognosis. More...
03 Nov 2026
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment

An investigational brush cytology test with a quantitative oral cancer index receives FDA Breakthrough. More...
03 Nov 2026
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

A new collaboration brings ESR1 and DPYD testing solutions developed by APIS Assay Technologies to market under BIOTYPE’s ExaccType brand.  More...
03 Nov 2026
Image Credit: Shutterstock

Blood Test Identifies Early Breast and Prostate Cancer Signals Years Before Diagnosis

A liquid biopsy DNA methylation test detects breast and prostate cancer signals up to eight years before diagnosis. More...
03 Nov 2026
Image: Researcher Joris Deelen (Photo courtesy of Elton Alisson/Agência FAPESP)

Blood-Based Score May Support Targeted Interventions for Healthier Aging

A new blood-based metabolic score using 10 routine markers predicts longevity and cardiometabolic risk. More...
03 Nov 2026
Image: Roche receives FDA 510(k) clearance for new cobas eplex respiratory pathogen panel 3 (Photo courtesy of Roche)

Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel

A new test enables rapid, customizable syndromic detection of 19 respiratory pathogens from a single swab in under two hours. More...
03 Nov 2026
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Copyright © 2000-2026 Globetech Media. All rights reserved.